Electromed, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Electromed, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $54.72M | Aug 27, 2024 |
| FY2024 | Jun 30, 2023 | $48.07M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $41.66M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $35.76M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $32.47M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $31.30M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $28.31M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $25.86M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $22.99M | Sep 5, 2017 |
| FY2016 | Jun 30, 2015 | $19.41M | Sep 6, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $64.00M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $54.72M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $48.07M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $41.66M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $35.76M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $32.47M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $31.30M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $28.31M | Aug 27, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $49.97M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $41.73M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $36.52M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $31.44M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $27.31M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $25.20M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $23.85M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $21.77M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $20.57M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $17.88M | Sep 5, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $7.54M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $5.15M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $3.17M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $2.31M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $2.36M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $4.16M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $1.98M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $1.83M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $2.23M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $2.21M | Sep 5, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $9.66M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $6.58M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $4.01M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $2.97M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $3.14M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $5.12M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $2.83M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $2.71M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $3.57M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $3.11M | Sep 5, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $996.0K | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $656.0K | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $916.0K | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $1.36M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $1.72M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $1.05M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $583.3K | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $251.4K | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $596.9K | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $380.4K | Sep 5, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $39.32M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $34.49M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $31.60M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $27.11M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $22.44M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $19.95M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $20.44M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $18.81M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $16.40M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $14.39M | Sep 5, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $11.39M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $9.07M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $1.32M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | ($686.0K) | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $3.08M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $4.20M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $2.59M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $2.44M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $1.19M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $2.17M | Sep 5, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $262.0K | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $287.0K | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $1.65M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $1.43M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $287.0K | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $844.0K | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $1.33M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $526.2K | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $618.8K | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $534.9K | Sep 5, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $53.80M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $52.23M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $45.81M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $41.36M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $37.11M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $33.25M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $29.40M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $27.39M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $23.06M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $20.58M | Sep 5, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $10.59M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $7.69M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $8.14M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $7.19M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $4.69M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $3.00M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $3.67M | Aug 25, 2020 |
| FY2018 | Jun 30, 2018 | $4.74M | Sep 25, 2018 |
| FY2018 | Jun 30, 2017 | $3.99M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $4.22M | Sep 5, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $43.21M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $44.55M | Aug 26, 2025 |
| FY2025 | Jun 30, 2023 | $37.67M | Aug 26, 2025 |
| FY2024 | Jun 30, 2022 | $34.17M | Aug 27, 2024 |
| FY2023 | Jun 30, 2021 | $32.42M | Aug 22, 2023 |
| FY2022 | Jun 30, 2020 | $30.25M | Aug 23, 2022 |
| FY2021 | Jun 30, 2019 | $25.74M | Aug 24, 2021 |
| FY2020 | Jun 30, 2018 | $22.58M | Aug 25, 2020 |
| FY2019 | Jun 30, 2017 | $19.83M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $16.36M | Sep 25, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $21.19M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $23.67M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $18.79M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $15.78M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $14.92M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $13.68M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | $9.52M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $7.55M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $4.96M | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | $2.73M | Sep 5, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $15.29M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | $16.08M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | $7.37M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | $8.15M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | $11.89M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $10.48M | Aug 24, 2021 |
| FY2015 | Jun 30, 2015 | $3.60M | Sep 15, 2015 |
| FY2015 | Jun 30, 2014 | $1.50M | Sep 15, 2015 |
| FY2015 | Jun 30, 2013 | $503.6K | Sep 15, 2015 |
| FY2014 | Jun 30, 2012 | $1.70M | Sep 23, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $1.15M | Sep 5, 2017 |
| FY2016 | Jun 30, 2016 | $1.20M | Sep 6, 2016 |
| FY2016 | Jun 30, 2015 | $1.25M | Sep 6, 2016 |
| FY2015 | Jun 30, 2014 | $1.30M | Sep 15, 2015 |
| FY2014 | Jun 30, 2013 | $1.39M | Sep 23, 2014 |
| FY2013 | Jun 30, 2012 | $1.66M | Sep 25, 2013 |
| FY2012 | Jun 30, 2011 | $2.02M | Sep 26, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 5, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 25, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 5, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 8.35M | Aug 26, 2025 |
| FY2025 | Jun 30, 2024 | 8.64M | Aug 26, 2025 |
| FY2024 | Jun 30, 2023 | 8.56M | Aug 27, 2024 |
| FY2023 | Jun 30, 2022 | 8.48M | Aug 22, 2023 |
| FY2022 | Jun 30, 2021 | 8.53M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | 8.57M | Aug 24, 2021 |
| FY2020 | Jun 30, 2019 | 8.41M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | 8.29M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | 8.23M | Sep 25, 2018 |
| FY2018 | Jun 30, 2016 | 8.19M | Sep 25, 2018 |